This raises the possibility of a complementary role for SETD2 and ZMYND11 in antagonizing cancer development, forming a coordinated axis in which SETD2-catalyzed H3K36me3 promotes ZMYND11 recruitment and inhibits KMT2A (Fig 7B). Here, ZMYND11 is linked to cancer.